Impact of Delayed Addition of Anti-EGFR Monoclonal Antibodies
on the Outcome of First-Line Therapy in Metastatic Colorectal
Cancer Patients: a Retrospective Registry-Based Analysis

J 2018

Impact of Delayed Addition of Anti-EGFR Monoclonal Antibodies on the Outcome of First-Line Therapy in Metastatic Colorectal Cancer Patients: a Retrospective Registry-Based Analysis

FIALA, Ondrej, Veronika VESKRNOVA, Renata CHLOUPKOVÁ, Alexandr POPRACH, Igor KISS et. al.

Základní údaje

Originální název

Impact of Delayed Addition of Anti-EGFR Monoclonal Antibodies on the Outcome of First-Line Therapy in Metastatic Colorectal Cancer Patients: a Retrospective Registry-Based Analysis

Autoři

FIALA, Ondrej (203 Česká republika), Veronika VESKRNOVA (203 Česká republika), Renata CHLOUPKOVÁ (203 Česká republika, domácí), Alexandr POPRACH (203 Česká republika, domácí), Igor KISS (203 Česká republika, domácí), Katerina KOPECKOVA (203 Česká republika), Ladislav DUŠEK (203 Česká republika, domácí), Lubomir SLAVICEK (203 Česká republika), Milan KOHOUTEK (203 Česká republika), Jindrich FINEK, Marek SVOBODA (203 Česká republika, domácí), Lubos PETRUZELKA (203 Česká republika), Ludmila BOUBLIKOVA (203 Česká republika), Josef DVORAK (203 Česká republika), Bohuslav MELICHAR (203 Česká republika) a Tomas BUCHLER (203 Česká republika, garant)

Vydání

Targeted Oncology, Dordrecht, Springer, 2018, 1776-2596

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 3.683

Kód RIV

RIV/00216224:14110/18:00105155

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1007/s11523-018-0597-7

UT WoS

000453659300007

Klíčová slova anglicky

Anti-EGFR Monoclonal Antibodies; Colorectal Cancer

Štítky

14110811, 14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 10. 2. 2019 13:57, Soňa Böhmová

Anotace

V originále

BackgroundThe addition of monoclonal antibodies targeting the epidermal growth factor receptor (anti-EGFR Abs) to chemotherapy for metastatic colorectal carcinoma (mCRC) is commonly delayed in the real-world clinical practice, usually because of late RAS testing results.ObjectiveTo determine whether delayed addition of anti-EGFR mAbs up to the fourth cycle of backbone chemotherapy adversely affected outcomes of mCRC patients treated with first-line regimens.Patients and MethodsClinical data of patients with histologically verified, RAS wild-type mCRC treated with first-line systemic therapy regimens containing anti-EGFR mAbs were retrospectively analysed from a national database. Patients were divided into three groups according to the timing of anti-EGFR mAbs addition to the chemotherapy backbone. Cohort A (n=401) included patients in whom anti-EGFR mAbs were added to chemotherapy from the first cycle, cohort B (n=71) patients with anti-EGFR mAbs added to chemotherapy from the second cycle, and cohort C (n=101) patients who had anti-EGFR mAbs added to chemotherapy from the third or fourth cycle.ResultsThree hundred and thirty-six (58.6%) patients received panitumumab and 237 (41.4%) patients received cetuximab. The median progression-free survival (PFS) of the whole cohort was 12.2months (95% confidence interval [CI] 10.9-13.5), and the median overall survival (OS) was 33.5months (95% CI 27.6-39.4). The median PFS and OS for patients treated with anti-EGFR mAbs added to chemotherapy were 12.9 (95% CI 11.5-14.3) and 30.6months (95% CI 25.2-36.1) for cohort A, 9.7 (95% CI 9.1-10.3) and not reached for cohort B, compared to 11.5 (95% CI 9.8-13.2) and 37.9months (95% CI 28.6-47.3) for cohort C, respectively.ConclusionsDelayed addition of anti-EGFR mAbs to first-line chemotherapy was not associated with inferior survival or response rates.

Citovat

FIALA, Ondrej, Veronika VESKRNOVA, Renata CHLOUPKOVÁ, Alexandr POPRACH, Igor KISS, Katerina KOPECKOVA, Ladislav DUŠEK, Lubomir SLAVICEK, Milan KOHOUTEK, Jindrich FINEK, Marek SVOBODA, Lubos PETRUZELKA, Ludmila BOUBLIKOVA, Josef DVORAK, Bohuslav MELICHAR a Tomas BUCHLER. Impact of Delayed Addition of Anti-EGFR Monoclonal Antibodies on the Outcome of First-Line Therapy in Metastatic Colorectal Cancer Patients: a Retrospective Registry-Based Analysis. Targeted Oncology. Dordrecht: Springer, 2018, roč. 13, č. 6, s. 735-743. ISSN 1776-2596. Dostupné z: https://dx.doi.org/10.1007/s11523-018-0597-7.

@article{1482502,
   author = {Fiala, Ondrej and Veskrnova, Veronika and Chloupková, Renata and Poprach, Alexandr and Kiss, Igor and Kopeckova, Katerina and Dušek, Ladislav and Slavicek, Lubomir and Kohoutek, Milan and Finek, Jindrich and Svoboda, Marek and Petruzelka, Lubos and Boublikova, Ludmila and Dvorak, Josef and Melichar, Bohuslav and Buchler, Tomas},
   article_location = {Dordrecht},
   article_number = {6},
   doi = {http://dx.doi.org/10.1007/s11523-018-0597-7},
   keywords = {Anti-EGFR Monoclonal Antibodies; Colorectal Cancer},
   language = {eng},
   issn = {1776-2596},
   journal = {Targeted Oncology},
   title = {Impact of Delayed Addition of Anti-EGFR Monoclonal Antibodies on the Outcome of First-Line Therapy in Metastatic Colorectal Cancer Patients: a Retrospective Registry-Based Analysis},
   volume = {13},
   year = {2018}
}

TY  - JOUR
ID  - 1482502
AU  - Fiala, Ondrej - Veskrnova, Veronika - Chloupková, Renata - Poprach, Alexandr - Kiss, Igor - Kopeckova, Katerina - Dušek, Ladislav - Slavicek, Lubomir - Kohoutek, Milan - Finek, Jindrich - Svoboda, Marek - Petruzelka, Lubos - Boublikova, Ludmila - Dvorak, Josef - Melichar, Bohuslav - Buchler, Tomas
PY  - 2018
TI  - Impact of Delayed Addition of Anti-EGFR Monoclonal Antibodies on the Outcome of First-Line Therapy in Metastatic Colorectal Cancer Patients: a Retrospective Registry-Based Analysis
JF  - Targeted Oncology
VL  - 13
IS  - 6
SP  - 735-743
EP  - 735-743
PB  - Springer
SN  - 17762596
KW  - Anti-EGFR Monoclonal Antibodies
KW  - Colorectal Cancer
N2  - BackgroundThe addition of monoclonal antibodies targeting the epidermal growth factor receptor (anti-EGFR Abs) to chemotherapy for metastatic colorectal carcinoma (mCRC) is commonly delayed in the real-world clinical practice, usually because of late RAS testing results.ObjectiveTo determine whether delayed addition of anti-EGFR mAbs up to the fourth cycle of backbone chemotherapy adversely affected outcomes of mCRC patients treated with first-line regimens.Patients and MethodsClinical data of patients with histologically verified, RAS wild-type mCRC treated with first-line systemic therapy regimens containing anti-EGFR mAbs were retrospectively analysed from a national database. Patients were divided into three groups according to the timing of anti-EGFR mAbs addition to the chemotherapy backbone. Cohort A (n=401) included patients in whom anti-EGFR mAbs were added to chemotherapy from the first cycle, cohort B (n=71) patients with anti-EGFR mAbs added to chemotherapy from the second cycle, and cohort C (n=101) patients who had anti-EGFR mAbs added to chemotherapy from the third or fourth cycle.ResultsThree hundred and thirty-six (58.6%) patients received panitumumab and 237 (41.4%) patients received cetuximab. The median progression-free survival (PFS) of the whole cohort was 12.2months (95% confidence interval [CI] 10.9-13.5), and the median overall survival (OS) was 33.5months (95% CI 27.6-39.4). The median PFS and OS for patients treated with anti-EGFR mAbs added to chemotherapy were 12.9 (95% CI 11.5-14.3) and 30.6months (95% CI 25.2-36.1) for cohort A, 9.7 (95% CI 9.1-10.3) and not reached for cohort B, compared to 11.5 (95% CI 9.8-13.2) and 37.9months (95% CI 28.6-47.3) for cohort C, respectively.ConclusionsDelayed addition of anti-EGFR mAbs to first-line chemotherapy was not associated with inferior survival or response rates.
ER  -

FIALA, Ondrej, Veronika VESKRNOVA, Renata CHLOUPKOVÁ, Alexandr POPRACH, Igor KISS, Katerina KOPECKOVA, Ladislav DUŠEK, Lubomir SLAVICEK, Milan KOHOUTEK, Jindrich FINEK, Marek SVOBODA, Lubos PETRUZELKA, Ludmila BOUBLIKOVA, Josef DVORAK, Bohuslav MELICHAR a Tomas BUCHLER. Impact of Delayed Addition of Anti-EGFR Monoclonal Antibodies on the Outcome of First-Line Therapy in Metastatic Colorectal Cancer Patients: a Retrospective Registry-Based Analysis. \textit{Targeted Oncology}. Dordrecht: Springer, 2018, roč.~13, č.~6, s.~735-743. ISSN~1776-2596. Dostupné z: https://dx.doi.org/10.1007/s11523-018-0597-7.

Podrobný výpis o publikaci